Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders Journal Article
| Authors: | Hyman, D. M.; Diamond, E. L.; Vibat, C. R. T.; Hassaine, L.; Poole, J. C.; Patel, M.; Holley, V. R.; Cabrilo, G.; Lu, T. T.; Arcila, M. E.; Chung, Y. R.; Rampal, R.; Lacouture, M. E.; Rosen, N.; Meric-Bernstam, F.; Baselga, J.; Kurzrock, R.; Erlander, M. G.; Janku, F.; Abdel-Wahab, O. |
| Article Title: | Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders |
| Abstract: | Patients with Langerhans cell histiocytosis (LCH) and Erdheim–Chester disease (ECD) have a high frequency of BRAFV600E mutations and respond to RAF inhibitors. However, detection of mutations in tissue biopsies is particularly challenging in histiocytoses due to low tumor content and stromal contamination. We applied a droplet-digital PCR assay for quantitative detection of the BRAFV600E mutation in plasma and urine cell-free (cf) DNA and performed a prospective, blinded study in 30 patients with ECD/LCH. There was 100% concordance between tissue and urinary cfDNA genotype in treatment-naïve samples. cfDNA analysis facilitated identification of previously undescribed KRASG12S -mutant ECD and dynamically tracked disease burden in patients treated with a variety of therapies. These results indicate that cfDNA BRAFV600E mutational analysis in plasma and urine provides a convenient and reliable method of detecting mutational status and can serve as a noninvasive biomarker to monitor response to therapy in LCH and ECD. Significance: Patients with BRAFV600E -mutant histiocytic disorders have remarkable responses to RAF inhibition, but mutation detection in tissue in these disorders is challenging. Here, we identify that analysis of plasma and urinary cfDNA provides a reliable method to detect the BRAFV600E mutation and monitor response to therapy in these disorders. |
| Keywords: | adolescent; adult; child; clinical article; controlled study; treatment response; aged; gene mutation; prospective study; sensitivity and specificity; polymerase chain reaction; biological marker; genotype; mutational analysis; oncogene; blood sampling; fluorodeoxyglucose f 18; histiocytosis; oncogene k ras; urinalysis; dna extraction; genomic dna; predictive value; langerhans cell histiocytosis; clinical trial (topic); vemurafenib; b raf gene; human; male; female; article; erdheim chester disease; droplet digital polymerase chain reaction; systemic histiocytic disorder |
| Journal Title: | Cancer Discovery |
| Volume: | 5 |
| Issue: | 1 |
| ISSN: | 2159-8274 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2015-01-01 |
| Start Page: | 64 |
| End Page: | 71 |
| Language: | English |
| DOI: | 10.1158/2159-8290.cd-14-0742 |
| PROVIDER: | scopus |
| PUBMED: | 25324352 |
| PMCID: | PMC5705028 |
| DOI/URL: | |
| Notes: | Export Date: 2 March 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work